Glaucoma is a disease usually treated with topical drugs, but the chronic use of preserved intraocular pressure (IOP)-lowering medications is associated with some symptoms of ocular surface toxicity. The ocular surface status should be evaluated regularly in glaucoma patients to ensure the detection and early treatment of pathological signs that might alter patients' quality of life. The author suggests a possible sequence of evaluations to examine symptoms (adopting vision-specific quality-of-life questionnaires) and signs (using low methodologies to analyse the ocular surface status) that can be easily performed in daily clinical practice.
1
Glaucoma is a chronic neuropathy in which the topical medications usually represent the standard of therapy:
2 the pressure-lowering eyedrops are generally preserved and may induce ocular surface disorders attributable both to the drugs themselves and to the drugs preservatives. In fact, the prolonged use of preserved topical drugs is an extrinsic cause of increased tear evaporation, which induces a toxic response from the ocular surface. Benzalkonium chloride (BAK) is the most commonly used preservative in ophthalmic solutions, especially in anti-glaucoma drugs; it has a well-known dose-dependent toxicity.
3,4
Its cellular toxicity has been experimentally demonstrated in in vitro studies of conjunctiva-derived and corneal cells. 5, 6 BAK excites the expression of inflammatory cell markers at the ocular surface, 7 causes epithelial cell damage, cell death by apoptosis and a decrease in goblet cell density leading to tear film instability and tear hyperosmolarity. [8] [9] [10] The subsequent surface epithelial cell damage and punctate epithelial keratitis interfere with surface wettability.
1 Dry eye represents a common disorder in the elderly 11, 12 but is usually insufficient to cause any severe symptoms. Age-related dry eye has been widely studied: Mahlers et al., in 1996 , reported that changes in lachrymal evaporation, volume and osmolarity of the tear film is significantly associated with normal ageing; 13 Craig and Tomlinson, 14 Sahlin 15 and Rolando, 4 did not point out any significant relation. In glaucoma patients over 40 years old, BAK-linked effects usually combine with age-related dry eye. 12 The impact of dry eye on a glaucoma patient's daily life, particularly symptoms of discomfort, is an important aspect to consider in the follow-up. In a recent study of 61 glaucoma patients topically treated, we pointed out that all patients with an ocular surface disease recorded lower quality-of-life scores versus patients without surface changes. 16 Authors will suggest a sequence of ophthalmic examinations that should be performed to glaucoma patients to point out ocular surface alterations in clinical practice.
It must be remembered that a poor correlation has been found between objective and subjective signs of dry eye disease, [17] [18] [19] underlining that a patient's self-assessment of dry eye severity may differently relate to objective signs.
Sequence of Tests
The diagnosis of ocular surface disease is based both on symptoms reported by the patients (history and 'dry eye questionnaires') and on signs recorded by the ophthalmologist (objective tests). 25 and the Glaucoma Symptom Scale (GSS). 26 To be routinely adopted into clinical practice, a questionnaire must be easy and fast to complete; for these reasons we suggest using OSDI and/or GSS.
Symptoms Tests
The OSDI is a disease-specific questionnaire used to quantify the specific impact of dry eye on vision related quality of life (see Figure 1 ).
It includes three subscales: ocular discomfort (OSDI-symptoms),
functioning (OSDI-function) and environmental triggers (OSDI-triggers). 24 The questions refer to a one-week recall period and possible responses refer to the frequency of the disturbance. OSDI subscale scores can range from zero to 100, with higher scores indicating more problems or symptoms. The OSDI score is calculated as: (sum of scores x 25) ÷ (the total number of questions answered). The OSDI evaluates the impact of dry eye with the following scores: 0-12 (normal), 13-22 (mild), [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] (moderate) and 33-100 (severe). This questionnaire has been reported to have excellent test-retest reliability and to effectively discriminate between normal, mild-to-moderate and severe ocular surface disease. 24 The GSS 26 is a disease-specific questionnaire used to quantify the specific impact of glaucoma either on visual ocular complaints or
How to Diagnose the Ocular Surface Disease in Treated Glaucoma Patients a micro-pipette and the patient is asked to blink several times. The TF-BUT is evaluated measuring the interval between a complete blink and the appearance of the first area of tear film break-up on the corneal tear film, using a cobalt blue filter on the slit lamp microscope.
The TF-BUT values greater than or equal to 10 seconds are coded as normal and TF-BUT values less than 10 seconds as abnormal. 29, 30 The TF-BUT is usually performed prior to grading.
Corneal staining can be determined with different dyes: with fluorescein, staining must be graded as quickly as possible after instillation, since the dye then diffuses rapidly into the tissue and its high luminosity blurs the stain margin; staining after lissamine green, persists at high contrast and may therefore be observed for a considerable period.
The presence of corneal staining can be defined as more than one dot of fluorescein staining over the corneal surface. Since fluorescein diffuses rapidly into tissues, it is to assess staining rapidly, in sequence, in the right and then the left eye, so that the staining patterns observed are equally crisp. Superficial punctate keratitis can be graded according to the corneal fluorescein staining scale by determining the area and density of the lesion on a zero to three scale, where zero indicates the absence of keratitis punctata, one equals mild (a few punctata of staining but less than 10% coverage of the corneal surface; two equals moderate (10-50% coverage of the corneal surface); and three equals severe (more than 50% coverage of the corneal surface [see Figure 3] ).
31
Lissamine green is available as impregnated strips or may be ordered as a pre-prepared solution. A 1% drop will give more intense staining.
Because the drop is well tolerated, no anaesthetic is required. Using white light of moderate intensity, staining at the corneal region and the interpalpebral region of the nasal and temporal conjunctiva is graded using the Oxford Scheme. 31 The severity designations used for lissamine green staining are the following: 0 to I is normal; II to III is mild to moderate; and IV to V is severe (see Figure 4) . Since this dye does not diffuse into the substantia propria of the conjunctiva, the staining pattern is retained for longer.
Discussion
Glaucoma is a chronic disease that is often treated with topical drugs. Unfortunately, the chronic use of most IOP-lowering medication is associated with some symptoms of toxicity, such as ocular 
